<DOC>
	<DOCNO>NCT00055471</DOCNO>
	<brief_summary>The primary purpose study determine safest dose ZD4054 ( Zibotentan ) men prostate cancer</brief_summary>
	<brief_title>A Phase IIa . Open-label , Multicenter , Dose-escalation Study Assess Tolerability Pharmacokinetics ZD4054 ( Zibotentan ) Given Orally Once Daily Subjects With Metastatic Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Men 18 year &amp; old Confirmed diagnosis prostate cancer bone metastases No 2 prior chemotherapy regimens No radiation , chemotherapy bisphosphonates past 4 week</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>prostate cancer</keyword>
	<keyword>Metastatic prostate cancer</keyword>
	<keyword>bone metastasis</keyword>
</DOC>